Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This study aims to describe the trichoscopic pattern of chemotherapy-induced alopecia and its changes during different phases of chemotherapy.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

This study found that exposure to aqueous dispersion resin in aerosol form increased lung weights and caused histopathological changes in animals at higher concentrations, with a no-observable-effect level at 30 mg/m³.

In this study, ethanamizuril was found to cause alopecia, biochemical changes, and organ damage at higher doses in rats, with a no-observed-adverse-effect level of 20 mg/kg over 30 days.

This case report suggests that topical St. John's wort oil may cause severe skin toxicity during radiotherapy for non-small cell lung cancer, acting as a significant radiosensitizer.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

This article reviews methotrexate's pharmacokinetics and toxicity, emphasizing the role of urinary excretion and leucovorin in avoiding most toxic reactions; it provides no new clinical results.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

In this study, researchers reported that a combined formulation of curcumin and piperine in niosomal nanoparticles shows promise as a treatment for paraquat-induced lung toxicity, potentially due to improved bioavailability and strong antioxidant properties.

This study found that treating paracoccidioidomycosis-infected mice with a nanoparticle formulation of itraconazole led to higher drug accumulation in lung, liver, and spleen tissues, improved treatment efficacy, and reduced side effects compared to traditional oral solutions.

This study found that using a pH-sensitive layered double hydroxide nanocarrier to deliver etoposide significantly reduced liver toxicity and enhanced the drug’s effectiveness in targeting and suppressing non-small cell lung cancer.

In this study, combining pemetrexed with cisplatin in non-small cell lung cancer patients improved immune function and had lower blood toxicity compared to cisplatin with gemcitabine, despite similar disease control rates and other side effects between the two treatment groups.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This study found that glycyrrhizic acid may reduce the cutaneous toxicity caused by Osimertinib in mice, suggesting its potential as an adjunct treatment in clinical settings.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study investigated the sub-acute toxicity of Eclipta alba extract in Wistar albino rats, finding generally comparable hematological and biochemical parameters to controls, but noted mild morphological liver and kidney changes at the highest dose, highlighting a key area for further safety research.

This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Flubendazole in a nanoemulsion can potentially treat lung cancer and cryptococcal meningitis effectively and safely.

This review explores the concept of cosmetic toxicity in Ayurveda, focusing on chemical hazards in cosmetics and their management, but provides no new clinical findings.

This article explores gender differences in lung cancer, noting a higher number of nonsmoking women over age 60 with lung cancer compared to men, and highlights potential hormonal and molecular influences; no new study results were presented.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.

This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.